This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
November 3–5, 2025
Vienna Congress and Convention Center, Vienna, AustriaNovember 11–12, 2025 | Digital Partnering

Per Lundin
Co-Founder and CEO at Evox Therapeutics
Speaker

Profile

Per Lundin is a serial entrepreneur who serves as Co-Founder & Chief Executive Officer of Evox Therapeutics Ltd. He has ~15 years' experience founding, leading and advising biotech companies developing advanced therapies. Prior to co-founding and building out Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune and inflammatory diseases, which was ultimately acquired in PE-led trade sale. Over the last two decades, Per has been involved in the formation of five biotech companies developing products based on technologies ranging from cell therapies and exosomes to peptide-based drugs and non-viral delivery systems. He currently serves as board director of Breakthrough T1D International and Breakthrough T1D UK, the leading non-profit funder of research to cure, treat and prevent type 1 diabetes. He is a qualified European Patent Attorney with extensive business development and licensing experience; Per earned his PhD from the Karolinska Institute, his Master of Science in Biotechnology Engineering from the Royal Institute of Technology, and his Master of Business Administration from Stockholm University School of Business.